These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Clinical pharmacokinetics of intravenous and oral bretylium tosylate in survivors of ventricular tachycardia or fibrillation: clinical application of a new assay for bretylium. Anderson JL; Patterson E; Wagner JG; Johnson TA; Lucchesi BR; Pitt B J Cardiovasc Pharmacol; 1981; 3(3):485-99. PubMed ID: 6168830 [TBL] [Abstract][Full Text] [Related]
8. Inactivation of acetylcholinesterase with a bretylium tosylate photoaffinity probe. Branchini BR; Lajiness EJ Biochim Biophys Acta; 1986 Oct; 884(1):135-41. PubMed ID: 3768408 [TBL] [Abstract][Full Text] [Related]
9. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Garrett ER; Green JR; Bialer M Biopharm Drug Dispos; 1982; 3(2):129-64. PubMed ID: 7104462 [TBL] [Abstract][Full Text] [Related]
10. Bretylium tosylate binds preferentially to muscarinic receptors labelled with [3H]oxotremorine M (SH or 'high affinity' receptors) in rat heart and brain cortex. Gillard M; Brunner F; Waelbroeck M; Svoboda M; Christophe J Eur J Pharmacol; 1989 Jan; 160(1):117-24. PubMed ID: 2714357 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of delta9-tetrahydrocannabinol in dogs. Garrett ER; Hunt CA J Pharm Sci; 1977 Mar; 66(3):395-407. PubMed ID: 845807 [TBL] [Abstract][Full Text] [Related]
13. Nomogram for bretylium dosing in renal impairment. Adir J; Narang PK; Josselson J Ther Drug Monit; 1985; 7(3):265-8. PubMed ID: 4049461 [TBL] [Abstract][Full Text] [Related]
14. Bretylium tosylate: profile of the only available class III antiarrhythmic agent. Anderson JL Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143 [TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of bretylium. Rapeport WG Clin Pharmacokinet; 1985; 10(3):248-56. PubMed ID: 3893841 [TBL] [Abstract][Full Text] [Related]
16. The excretion and stability to metabolism of bretylium. DUNCOMBE WG; McCOUBREY A Br J Pharmacol Chemother; 1960 Jun; 15(2):260-4. PubMed ID: 13818641 [TBL] [Abstract][Full Text] [Related]
17. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Perentesis GP; Piltz GW; Kirshcenbaum HL; Navalakha P; Aronoff W; Cutie AJ Am J Hosp Pharm; 1983 Jun; 40(6):1010-2. PubMed ID: 6869385 [TBL] [Abstract][Full Text] [Related]
18. Interaction of bretylium tosylate with rat cardiac muscarinic receptors. Possible pharmacological relevance to antiarrhythmic action. Schreiber G; Friedman M; Sokolovsky M Circ Res; 1984 Nov; 55(5):653-9. PubMed ID: 6488487 [TBL] [Abstract][Full Text] [Related]
19. Disposition of bretylium in man and rat. A sensitive chemical method for its estimation in plasma and urine. Kuntzman R; Tsai I; Chang R; Conney AH Clin Pharmacol Ther; 1970; 11(6):829-37. PubMed ID: 5481571 [No Abstract] [Full Text] [Related]
20. Muscarinic receptor heterogeneity revealed by interaction with bretylium tosylate. Different ligand-receptor conformations versus different receptor subclasses. Schreiber G; Sokolovsky M Mol Pharmacol; 1985 Jan; 27(1):27-31. PubMed ID: 3965929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]